Given the strong association between USP5 expression, oncogenic signaling activation, and poor clinical outcomes, our results suggest that targeting USP5 and its downstream pathways could be a promising therapeutic strategy to mitigate the malignant potential of this subpopulation in HNSCC. Here, USP5 is linked to head and neck squamous cell carcinoma.